fda glp-1 warning september 2025 news Issues 30 Letters to Telehealth Firms Over Misleading Compounded Marketing Fmr. FDA Commissioner weighs in

What constitutes unresponsive: Clinically, per manufacture, a patient should not be considered as unresponsive to therapy until less than 5% weight loss over the course of 3 months of Semaglutide at 2.4 mg=100 units/wk has been established

Additionally, it is widely recognized that nanoparticles smaller than 500 nm can evade the reticuloendothelial system (RES), thereby prolonging their circulation time 47

Both compounds share a phenolic hydroxyl group in their structure, enabling them to directly neutralize ROS and interrupt chain reactions that propagate oxidative damage

How many sessions are required for visible results

No approved therapeutic claims